公开(公告)号：US20230270877A1

公开(公告)日：2023-08-31

申请号：US18309388

申请日：2023-04-28

申请人： Seagen Inc.

发明人： Shyra Gardai ,  Alyson Smith ,  Kerry Klussman ,  Bernard Liu ,  Heather Van Epps

IPC分类号： A61K47/68 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K47/6851 ,  A61K39/3955 ,  A61K47/6817 ,  A61K47/6889 ,  A61K47/6829 ,  A61P35/00

摘要： Provided herein are methods of treating cancer with an antibody that binds an immune cell engager in combination with an antibody-drug conjugate.

公开(公告)号：US20230270876A1

公开(公告)日：2023-08-31

申请号：US18178886

申请日：2023-03-06

申请人： Novartis AG

发明人： Bernhard Hubert Geierstanger ,  Weijia Ou ,  Tetsuo Uno

IPC分类号： A61K47/68 ,  C07K16/32

CPC分类号： A61K47/6817 ,  C07K16/32 ,  A61K47/6855 ,  A61K47/6871 ,  A61K47/6803 ,  C07K16/2863

摘要： The present invention provides specific sites for modifying antibodies or antibody fragments by replacing at least one native amino acid in the constant region of a parental antibody or antibody fragment with cysteine, which can be used as a site of attachment for a payload or linker-payload combination.

公开(公告)号：US20230265183A1

公开(公告)日：2023-08-24

申请号：US17996403

申请日：2021-04-21

申请人： MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

发明人： Hongyuan REN ,  Jian ZHU ,  Jian LIN ,  Lichun WANG ,  Xiaohong XU ,  Xiaofang DENG ,  Jianjun BI ,  Jin WANG ,  Jian WU

IPC分类号： C07K16/28 ,  G01N33/574 ,  A61K47/68 ,  A61P35/00 ,  A61P15/00

CPC分类号： C07K16/28 ,  A61K47/6817 ,  A61K47/6849 ,  A61K47/6855 ,  A61P15/00 ,  A61P35/00 ,  G01N33/57492 ,  A61K2039/505

摘要： Provided is an antibody molecule that binds to human Nectin-4 or a fragment thereof. The antibody is obtained by means of hybridoma screening and humanization techniques, and is used for the prevention or treatment of a cancer, and may be used as a clinical lead drug molecule.

公开(公告)号：US11667696B2

公开(公告)日：2023-06-06

申请号：US16580290

申请日：2019-09-24

申请人： Seagen Inc.

发明人： Damon L. Meyer

IPC分类号： C07K16/00 ,  A61K47/68 ,  C07K1/36 ,  C07K1/08 ,  C07K1/113

CPC分类号： C07K16/00 ,  A61K47/68 ,  A61K47/6817 ,  A61K47/6889 ,  C07K1/086 ,  C07K1/1133 ,  C07K1/36 ,  C07K2317/52 ,  C07K2317/53

摘要： The present invention provides a method for making uncapped cysteine protein preparations, including uncapped engineered cysteine antibody preparations. The methods include, inter alia, contacting a reducing agent with engineered cysteine antibody molecules, each of the antibody molecules having at least one capped engineered cysteine residue and at least one interchain disulfide bond and reacting the reducing agent with the antibody molecules under conditions sufficient to uncap engineered cysteine residues and form cap byproducts. The method also includes removing the cap byproduct during the reduction reaction. Substantially all of the interchain disulfide bonds present in the antibody molecules prior to reduction are retained following reduction. Antibody conjugates and methods for preparing antibody conjugates using uncapped antibody preparations are also described.

公开(公告)号：US20230149557A1

公开(公告)日：2023-05-18

申请号：US17917064

申请日：2021-04-22

申请人： SANOFI

发明人： Céline NICOLAZZI

IPC分类号： A61K47/68 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K47/6853 ,  A61K47/6803 ,  A61K47/6889 ,  A61K39/3955 ,  A61P35/00 ,  A61K47/6805 ,  A61K47/6817 ,  A61K2039/545

摘要： The present invention concerns antibody-conjugates comprising an anti-CEACAM5-antibody for use for treating cancer in combination with cetuximab. The invention further relates to pharmaceutical compositions and kit-of-parts comprising an anti-CEA-CAM5-antibody in combination with cetuximab for use for treating cancer.

公开(公告)号：US20190192682A1

公开(公告)日：2019-06-27

申请号：US16289388

申请日：2019-02-28

申请人： Magenta Therapeutics, Inc.

发明人： Andrew Nixon ,  Dwight Morrow ,  Adam Hartigan

IPC分类号： A61K47/68 ,  C12N5/0789 ,  C07K16/28 ,  A61P35/02 ,  A61K38/12 ,  A61K35/12 ,  A61P37/06 ,  C07K14/37

CPC分类号： A61K47/6817 ,  A61K35/12 ,  A61K38/12 ,  A61K39/395 ,  A61K47/6849 ,  A61K47/6897 ,  A61K2035/124 ,  A61P35/02 ,  A61P37/06 ,  C07K14/37 ,  C07K16/289 ,  C07K2317/73 ,  C12N5/0087 ,  C12N5/0647 ,  C12N2501/599

摘要： The invention provides compositions and methods useful for the depletion of cells, such as CD45+, CD135+, CD34+, CD90+, and/or CD110+ cells, and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.

公开(公告)号：US20180333504A1

公开(公告)日：2018-11-22

申请号：US15975191

申请日：2018-05-09

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Amy HAN ,  William OLSON

IPC分类号： A61K47/68 ,  A61K47/61

CPC分类号： A61K47/6807 ,  A61K31/566 ,  A61K31/724 ,  A61K47/61 ,  A61K47/6803 ,  A61K47/6817 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6889 ,  A61P3/00 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  A61P35/04 ,  C07J43/003 ,  C07J71/0031

摘要： Provided herein are compounds, compositions, conjugates and methods for the treatment of diseases, and/or conditions such as, but not limited to, proliferative diseases. In certain embodiments, compounds, compositions, and conjugates are provided, which include cyclodextrin-based linker-payloads and protein conjugates thereof, and/or in combination with other agents. By administering these compounds, compositions, and conjugates as described herein to specific target cells, side-effects due to non-specific binding phenomena, for example, to non-target cells are reduced.

公开(公告)号：US20180251567A1

公开(公告)日：2018-09-06

申请号：US15983361

申请日：2018-05-18

申请人： Genentech, Inc.

发明人： Mark Dennis ,  Bonnee Rubinfeld ,  Paul Polakis

IPC分类号： C07K16/30 ,  G01N33/574 ,  A61K47/68 ,  A61K31/537 ,  A61K45/06 ,  C07K16/18 ,  C07K16/28 ,  A61K39/00

CPC分类号： C07K16/30 ,  A61K31/537 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6813 ,  A61K47/6817 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6857 ,  A61K47/6869 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/28 ,  C07K16/3023 ,  C07K16/3069 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/57423 ,  G01N33/57449 ,  G01N33/57492

摘要： The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

公开(公告)号：US20180244717A1

公开(公告)日：2018-08-30

申请号：US15961531

申请日：2018-04-24

申请人： NOVARTIS AG

发明人： Bernhard Hubert GEIERSTANGER ,  Jan GRUNEWALD ,  Yunho JIN ,  Weijia OU ,  Tetsuo UNO ,  Yongqin WAN ,  Xing WANG

IPC分类号： C07K5/02 ,  C07K7/02 ,  A61K47/68 ,  C07K16/32

CPC分类号： C07K5/0205 ,  A61K47/6817 ,  A61K47/6851 ,  C07K7/02 ,  C07K16/32

摘要： Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.

公开(公告)号：US20180193477A1

公开(公告)日：2018-07-12

申请号：US15741984

申请日：2016-07-15

申请人： Zymeworks Inc.

发明人： Gordon Yiu Kon Ng ,  Leonard G. Presta ,  Thomas Spreter Von Kreudenstein

IPC分类号： A61K47/68 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  C07K16/28 ,  A61K51/10 ,  C07K16/32 ,  A61K45/06 ,  A61K39/395 ,  C07K16/46

CPC分类号： A61K47/6803 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6811 ,  A61K47/6817 ,  A61K47/6835 ,  A61K47/6849 ,  A61K47/6855 ,  A61K47/6869 ,  A61K47/6879 ,  A61K51/1027 ,  A61K51/103 ,  A61K51/1042 ,  A61K51/1051 ,  A61K51/1072 ,  A61K2039/505 ,  A61K2039/572 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/32 ,  C07K16/46 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C40B40/02 ,  C40B40/08

摘要： Bispecific antigen-binding constructs e.g., antibodies conjugated to drugs (ADCs), which bind CD3 and other cell-surface target antigen such as tumor antigens e.g., CD19, CDH3, HER2, HER3 and EGFR antigens and methods of use are disclosed.